Janumet Xr Patent Expiration

JANUMET XR's oppositions filed in EPO
JANUMET XR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326708 MSD SUB MERCK Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6340475 MSD SUB MERCK Extending the duration of drug release within the stomach during the fed mode
Sep, 2016

(7 years ago)

US6635280 MSD SUB MERCK Extending the duration of drug release within the stomach during the fed mode
Sep, 2016

(7 years ago)

US6303661 MSD SUB MERCK Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US6890898 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7459428 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7125873 MSD SUB MERCK Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 11 months ago)

US6699871 MSD SUB MERCK Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 11 months ago)

US6699871

(Pediatric)

MSD SUB MERCK Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 5 months ago)

US7125873

(Pediatric)

MSD SUB MERCK Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 5 months ago)

US7326708

(Pediatric)

MSD SUB MERCK Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(2 years from now)



Janumet Xr is a drug owned by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc. It is used for managing type 2 diabetes mellitus with the combination of sitagliptin and metformin HCl extended release, either alone or with insulin. Janumet Xr uses Metformin Hydrochloride; Sitagliptin Phosphate as an active ingredient. Janumet Xr was launched by Msd Sub Merck in 2012. It is is available in tablet, extended release form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 24, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
M(M-244) Aug 12, 2022
Pediatric Exclusivity(PED) Jun 04, 2024
M(M-187) Dec 04, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 02 February, 2012

Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate; Method of treating type 2 diabetes mellitus in patie...

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of JANUMET XR before it's drug patent expiration?
More Information on Dosage

JANUMET XR family patents

Family Patents